☆ 4.5 Editorial Material

Targeted covalent inhibitors for novel therapeutics

FUTURE MEDICINAL CHEMISTRY (2023)

Related references

Note: Only part of the references are listed.

Review Chemistry, Medicinal

An update on the discovery and development of reversible covalent inhibitors

Faridoon et al.

Summary: Small molecule drugs that covalently bind irreversibly to their target proteins have advantages such as increased duration of action and less-frequent drug dosing. However, the challenges of irreversible covalent drugs include potential off-target toxicities and immunogenicity risks. Incorporating reversibility into covalent drugs can reduce off-target toxicity and improve safety.

MEDICINAL CHEMISTRY RESEARCH (2023)

Add to Collection

Review Pharmacology & Pharmacy

Electrophilic warheads in covalent drug discovery: an overview

Nikolett Peczka et al.

Summary: This review provides an overview of electrophilic warheads used for protein labeling in chemical biology and medicinal chemistry. The warheads are discussed based on targeted residues, mechanism, and selectivity, and analyzed using multiple datasets. Despite the availability of numerous electrophilic warheads, only a fraction of them are used in current drug discovery projects. Recent studies have identified new tractable residues, but the discovery of new warheads for these residues is still needed.

EXPERT OPINION ON DRUG DISCOVERY (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Xiaoyun Lu et al.

Summary: Small molecule covalent kinase inhibitors (CKIs) have advantages for sustained target inhibition and high selectivity, with major medicinal chemistry strategies involving the addition of a warhead to a reversible lead/inhibitor scaffold to generate CKIs, while also facing challenges in drug discovery in this area.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Oncology

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Kai Fu et al.

Summary: Osimertinib is an effective treatment for advanced NSCLC patients with EGFR mutations, but acquired resistance limits its efficacy. This article comprehensively summarizes the resistance mechanisms of osimertinib and discusses potential therapeutic strategies for EGFR-mutated NSCLC patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Advances in covalent drug discovery

Lydia Boike et al.

Summary: Covalent drugs have been widely used for over a century, but recent advances in tools for rational design have led to the successful development of potent and selective inhibitors, such as KRAS(G12C) inhibitors. The use of electrophile-first approaches and the emergence of chemoproteomics platforms have greatly enhanced the discovery and development of covalent drugs.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Applications of covalent chemistry in targeted protein degradation

Dong Lu et al.

Summary: Proteolysis-targeting chimeras (PROTACs) and targeted covalent inhibitors (TCIs) are two exciting strategies in the fields of chemical biology and drug discovery. The emergence of covalent PROTACs, which combine these two strategies, has gained increasing interest in recent years. This review highlights the mechanism and advantages of TCIs and PROTACs, and discusses the recent development of covalent PROTACs using irreversible and reversible covalent chemistry.

CHEMICAL SOCIETY REVIEWS (2022)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

KRAS mutation: from undruggable to druggable in cancer

Lamei Huang et al.

Summary: This review provides the latest understanding of fundamental aspects of KRAS, the relationship between KRAS mutations and tumor immune evasion, and new progress in targeting KRAS, particularly KRAS (G12C). The possible mechanisms of resistance to KRAS (G12C) inhibitors and potential combination therapies are also summarized, aiming to offer the best personalized treatment regimen with KRAS (G12C) inhibitors and achieve truly precise treatment.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Recent advances in the development of covalent inhibitors

Hyunsoo Kim et al.

Summary: The use of covalent inhibitors in drug discovery has gained significant attention in the 2000s, with over 50 covalent drugs currently on the market and more in development. This review aims to provide an understanding of covalent inhibitors by exploring their characteristics, mechanisms, and potential applications, as well as introducing the latest covalent warheads for inhibitor development.

RSC MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Chemistry, Medicinal

Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology

Matthias Gehringer et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

Add to Collection

Article Chemistry, Medicinal

Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer

Lingfeng Chen et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

The Taxonomy of Covalent Inhibitors

Alfred Tuley et al.

BIOCHEMISTRY (2018)

Add to Collection

Review Chemistry, Multidisciplinary

Structure-based design of targeted covalent inhibitors

Richard Lonsdale et al.

CHEMICAL SOCIETY REVIEWS (2018)

Add to Collection

Review Pharmacology & Pharmacy

Progress with covalent small-molecule kinase inhibitors

Zheng Zhao et al.

DRUG DISCOVERY TODAY (2018)

Add to Collection

Article Biochemical Research Methods

A Perspective on the Kinetics of Covalent and Irreversible Inhibition

John M. Strelow

SLAS DISCOVERY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Covalent inhibitors: an opportunity for rational target selectivity

Roman Lagoutte et al.

CURRENT OPINION IN CHEMICAL BIOLOGY (2017)

Add to Collection

Article Chemistry, Medicinal

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer

Zhendong Song et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Add to Collection

Article Chemistry, Medicinal

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

Tjeerd Barf et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Crystal Structures of Covalent Complexes of β-Lactam Antibiotics with Escherichia coli Penicillin-Binding Protein 5: Toward an Understanding of Antibiotic Specificity

George Nicola et al.

BIOCHEMISTRY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.